From CNBC: 2024-09-12 11:49:23

Gilead’s lenacapavir injection reduces HIV infections by 96% in a second large study, likely leading to FDA approval for HIV prevention. The drug shows 100% efficacy in preventing HIV and is 89% more effective than Truvada, with no new safety concerns and positive results across multiple study populations. Gilead shares rose over 1% following the announcement.



Read more at CNBC: Gilead Lenacapavir cut HIV infections by 96% in trial